2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-113283
    Homogentisic acid 451-13-8 ≥98.0%
    Homogentisic acid is a specific metabolite in urine and serum, which is used for diagnosis of alkaptonuria.
    Homogentisic acid
  • HY-113373
    Guanidinosuccinic acid 6133-30-8 ≥98.0%
    Guanidinosuccinic acid is a nitrogenous metabolite.
    Guanidinosuccinic acid
  • HY-115642
    preQ1 dihydrochloride 86694-45-3 ≥98.0%
    preQ1 dihydrochloride is a modified, guanine-derived nucleobase and a precursor of Queuine (HY-N10574) biosynthesis. preQ1 dihydrochloride binds to the aptamer of PreQ1 riboswitch with high affinity.
    preQ1 dihydrochloride
  • HY-125145
    AA92593 457961-34-1 99.94%
    AA92593 is a selective and competitive melanopsin OPN4 antagonist.
    AA92593
  • HY-128425
    N-​Carbamoyl-​DL-​aspartic acid 923-37-5 ≥98.0%
    N-​Carbamoyl-​DL-​aspartic acid (Ureidosuccinic acid) is a precursor of nucleic acid pyrimidines. N-​Carbamoyl-​DL-​aspartic acid has antitumor activities.
    N-​Carbamoyl-​DL-​aspartic acid
  • HY-148814
    BI-3231 2894848-07-6 99.83%
    BI 3231 is a potent and selective hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13) inhibitor, with IC50s of 1 and 13 nM for hHSD17B13 and mHSD17B13, respectively. BI 3231 has the potential for the research of nonalcoholic steatohepatitis (NASH) and other liver diseases.
    BI-3231
  • HY-151257
    IHMT-MST1-58 2414484-25-4 99.05%
    IHMT-MST1-58 is a potent, selective mammalian and orally active STE20-like protein 1 kinase (MST1) inhibitor with IC50 value of 23 nM. IHMT-MST1-58 can be used for the research of Type 1/2 diabetes.
    IHMT-MST1-58
  • HY-152221
    PCSK9-IN-10 368434-98-4 98.95%
    PCSK9-IN-10 is a potent and orally active PCSK9 inhibitor with an IC50 value of 6.4 µM. PCSK9-IN-10 increases the expression of LDLR protein and decreases the expression of PCSK9. PCSK9-IN-10 reduces atherosclerosis progression. PCSK9-IN-10 has the potential for the research of hyperlipidemia.
    PCSK9-IN-10
  • HY-15687A
    SAR407899 923359-38-0 99.60%
    SAR407899 is a selective, potent and ATP-competitive ROCK inhibitor, with an IC50 of 135 nM for ROCK-2, and Kis of 36 nM and 41 nM for human and rat ROCK-2, respectively. SAR407899 shows stable inhibition of migrasome formation.
    SAR407899
  • HY-N10574
    Queuine 72496-59-4 99.67%
    Queuine is a selective substrate for tRNA guanine transglycosylase (TGT) and can be incorporated into eukaryotic tRNA. Queuine promotes tRNA modification, affecting mitochondrial function and Warburg metabolic phenotype. If Queuine is deficient, aerobic glycolysis can be enhanced, oxidative phosphorylation can be inhibited, and Warburg metabolism can be promoted, accompanied by increased ammonia and lactate production and increased lactate dehydrogenase activity. Queuine can be used for autoimmune diseases (such as experimental models of multiple sclerosis) and cancer metabolic regulation, and its deficiency is associated with low tRNA modification in tumor cells.
    Queuine
  • HY-106376C
    L-Buthionine-(S,R)-sulfoximine hydrochloride ≥98.0%
    L-Buthionine-(S,R)-sulfoximine hydrochloride is a cell-permeable, potent, fast acting, orally active and irreversible inhibitor of g-glutamylcysteine synthetase and depletes cellular glutathione levels. The IC50 value of L-Buthionine-(S,R)-sulfoximine on melanoma, breast and ovarian tumor specimens are 1.9 μM, 8.6 μM, and 29 μM, respectively.
    L-Buthionine-(S,R)-sulfoximine hydrochloride
  • HY-145934A
    UDP-GlcNAz disodium 1611490-64-2 99.74%
    UDP-GlcNAz disodium (UDP-N-azidoacetylgalactosamine disodium) is the analogue of UDP-GlcNAc (HY-112174). UDP-GlcNAc is the donor substrate of many N-acetylgalactosaminyltransferases, enzymes which transfer GlcNAc from the nucleotide sugar to a saccharide or peptide acceptor. UDP-GlcNAc (disodium) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    UDP-GlcNAz disodium
  • HY-W009390
    DL-Homocystine 870-93-9 ≥98.0%
    DL-Homocystine is the double-bonded form of homocysteine and homocysteine is recognized as an important substance in the pathogenesis and pathophysiology of schizophrenia.
    DL-Homocystine
  • HY-W013159
    2'-Deoxyguanosine 5'-monophosphate disodium 33430-61-4 99.85%
    2'-Deoxyguanosine 5'-monophosphate (5′-dGMP) disodium is a mononucleotide having guanine as the nucleobase. 2'-Deoxyguanosine 5'-monophosphate disodium is a reactant involved in analysis of self-assembling in solution and nucleation/growth of G-qudruplexes, nucleophilic trapping and reductive alkylation. 2'-Deoxyguanosine 5'-monophosphate disodium can be used as an oxidizable target. 2'-Deoxyguanosine 5'-monophosphate disodium is a nucleic acid guanosine triphosphate (GTP) derivative and is a nucleotide precursor used in DNA synthesis.
    2'-Deoxyguanosine 5'-monophosphate disodium
  • HY-W013268
    (S)-(+)-N-3-Benzylnirvanol 790676-40-3 ≥98.0%
    (S)-(+)-N-3-Benzylnirvanol ((+)-N-3-Benzylnirvanol) is a selective and competitive cytochrome P450 (CYP) isoform CYP2C19 inhibitor with a Ki of 250 nM. (S)-(+)-N-3-Benzylnirvanol has low activity against CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2D6, CYP2E1, and CYP3A4.
    (S)-(+)-N-3-Benzylnirvanol
  • HY-W013579
    (S)-(+)-Carvone 2244-16-8 99.26%
    (S)-(+)-Carvone is an orally active natural product. (S)-(+)-Carvone increases the activity of antioxidant enzymes (SOD, CAT) and ROS, reduces the levels of oxidative stress markers (MDA, AChE), reduces the secretion of proinflammatory cytokines (IL-1β, IL-4, IL-6, IL-10), and downregulates NLRP3. (S)-(+)-Carvone increases the activities of caspase-8, -9 and -3. (S)-(+)-Carvone induces apoptotic death. (S)-(+)-Carvone has antimanic-like effect, liver protection and anticancer activity against skin cancer. (S)-(+)-Carvone improves memory and arthritis.
    (S)-(+)-Carvone
  • HY-W014787
    Decanedioic acid 111-20-6
    Decanedioic acid is a straight-chain dicarboxylic acid. Dodecanedioic acid overcomes metabolic inflexibility in type 2 diabetes. Decanedioic acid prevents and reverses metabolic-associated liver disease and obesity. Decanedioic acid is associated with carnitine-acylcarnitine translocase deficiency and medium chain acyl-CoA dehydrogenase deficiency.
    Decanedioic acid
  • HY-W015608
    2-Phenylpropionic acid 492-37-5
    2-Phenylpropionic acid is an intermediate in alpha-Methylstyrene metabolism.
    2-Phenylpropionic acid
  • HY-W018004
    L-Homocitrulline 1190-49-4
    L-Homocitrulline is metabolized to homoarginine through homoargininosuccinate via the urea cycle pathway and its metabolic abnormality could lead to Lysinuric Protein Intolerance (LPI).
    L-Homocitrulline
  • HY-W142080
    α-Methyl-DL-tryptophan 153-91-3 99.92%
    α-Methyl-DL-tryptophan (α-Methyltryptophan), a tryptophan derivative, is a selective SLC6A14 blocker. In estrogen receptor (ER)-positive breast cancer cells, α-Methyl-DL-tryptophan inhibits mTOR and activates autophagy and apoptosis. α-Methyl-DL-tryptophan also has the effect of reducing weight.
    α-Methyl-DL-tryptophan
Cat. No. Product Name / Synonyms Application Reactivity